ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Opfan17
|
572 |
250K |
72 |
06/12/20 |
06/12/20 |
ASX - By Stock
|
572
|
250K
|
72
|
|
ASX - By Stock
|
MSB |
Re:
AGM Discussion
|
|
Opfan17
|
254 |
100K |
68 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
254
|
100K
|
68
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
64 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
17K
|
6.6M
|
64
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Opfan17
|
555 |
266K |
13 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
555
|
266K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
MSB to dispute FDA finding in Type A meeting
|
|
Opfan17
|
1.0K |
500K |
53 |
06/10/20 |
06/10/20 |
ASX - By Stock
|
1.0K
|
500K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Next steps discussion
|
|
Opfan17
|
52 |
21K |
4 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
52
|
21K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
93 |
26/09/20 |
26/09/20 |
ASX - By Stock
|
17K
|
6.6M
|
93
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
17 |
22/09/20 |
22/09/20 |
ASX - By Stock
|
17K
|
6.6M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
45 |
19/09/20 |
19/09/20 |
ASX - By Stock
|
17K
|
6.6M
|
45
|
|
ASX - By Stock
|
MSB |
Re:
Regenerative Medicine and Cell Therapies Virtual Event
|
|
Opfan17
|
129 |
56K |
11 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
129
|
56K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
11 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
17K
|
6.6M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
132 |
06/09/20 |
06/09/20 |
ASX - By Stock
|
17K
|
6.6M
|
132
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial
|
|
Opfan17
|
299 |
138K |
47 |
04/09/20 |
04/09/20 |
ASX - By Stock
|
299
|
138K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
136 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
17K
|
6.6M
|
136
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
Opfan17
|
2.0K |
681K |
61 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
681K
|
61
|
|
ASX - By Stock
|
MSB |
Re:
FDA ODAC Meeting Material discussion analysis
|
|
Opfan17
|
491 |
191K |
40 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
491
|
191K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
FDA ODAC Meeting Material discussion analysis
|
|
Opfan17
|
491 |
191K |
43 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
491
|
191K
|
43
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
Opfan17
|
854 |
426K |
30 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
854
|
426K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
32 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
17K
|
6.6M
|
32
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
92 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
17K
|
6.6M
|
92
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
34 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
17K
|
6.6M
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
Opfan17
|
854 |
426K |
5 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
854
|
426K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
Opfan17
|
425 |
188K |
31 |
25/07/20 |
25/07/20 |
ASX - By Stock
|
425
|
188K
|
31
|
|
ASX - By Stock
|
MSB |
Re:
ARDS Trial - From UPenn Principal Investigator
|
|
Opfan17
|
41 |
26K |
161 |
23/07/20 |
23/07/20 |
ASX - By Stock
|
41
|
26K
|
161
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
39 |
22/07/20 |
22/07/20 |
ASX - By Stock
|
23K
|
13M
|
39
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
36 |
21/07/20 |
21/07/20 |
ASX - By Stock
|
17K
|
6.6M
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
Opfan17
|
425 |
188K |
95 |
19/07/20 |
19/07/20 |
ASX - By Stock
|
425
|
188K
|
95
|
|
ASX - By Stock
|
MSB |
Re:
Countdown to Interim Analysis
|
|
Opfan17
|
195 |
71K |
9 |
18/07/20 |
18/07/20 |
ASX - By Stock
|
195
|
71K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Countdown to Interim Analysis
|
|
Opfan17
|
195 |
71K |
111 |
15/07/20 |
15/07/20 |
ASX - By Stock
|
195
|
71K
|
111
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
56 |
14/07/20 |
14/07/20 |
ASX - By Stock
|
17K
|
6.6M
|
56
|
|
ASX - By Stock
|
MSB |
Re:
REVASCOR - CHF Insurance Coverage
|
|
Opfan17
|
79 |
29K |
26 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
79
|
29K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
Opfan17
|
518 |
262K |
47 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
518
|
262K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
Opfan17
|
425 |
188K |
7 |
06/07/20 |
06/07/20 |
ASX - By Stock
|
425
|
188K
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
46 |
03/07/20 |
03/07/20 |
ASX - By Stock
|
23K
|
13M
|
46
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
17 |
01/07/20 |
01/07/20 |
ASX - By Stock
|
17K
|
6.6M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Opfan17
|
1.0K |
487K |
43 |
29/06/20 |
29/06/20 |
ASX - By Stock
|
1.0K
|
487K
|
43
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Opfan17
|
1.0K |
487K |
37 |
28/06/20 |
28/06/20 |
ASX - By Stock
|
1.0K
|
487K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
74 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
17K
|
6.6M
|
74
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
3 |
23/06/20 |
23/06/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
30 |
23/06/20 |
23/06/20 |
ASX - By Stock
|
17K
|
6.6M
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
12 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
17K
|
6.6M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
13 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
17K
|
6.6M
|
13
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
121 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
23K
|
13M
|
121
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
29 |
17/06/20 |
17/06/20 |
ASX - By Stock
|
23K
|
13M
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Opfan17
|
1.0K |
487K |
6 |
17/06/20 |
17/06/20 |
ASX - By Stock
|
1.0K
|
487K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Opfan17
|
1.0K |
487K |
24 |
17/06/20 |
17/06/20 |
ASX - By Stock
|
1.0K
|
487K
|
24
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
37 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
23K
|
13M
|
37
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
24 |
12/06/20 |
12/06/20 |
ASX - By Stock
|
23K
|
13M
|
24
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
18 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
23K
|
13M
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Countdown to Interim Analysis
|
|
Opfan17
|
195 |
71K |
16 |
09/06/20 |
09/06/20 |
ASX - By Stock
|
195
|
71K
|
16
|
|